Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212557 | 0.86 | P2RX7 (0.35) | ELANEP2RX7CA1CA2LMNA | |
| SCHEMBL9900673 | 0.85 | P2RX7 (0.34) | ELANEP2RX7CA1CA2LMNA | |
| SCHEMBL9942946 | 0.80 | CA1 (0.33) | ELANEP2RX7CA1CA2LMNA | |
| SCHEMBL85989 | 0.79 | RORC (0.34) | — | |
| SCHEMBL9942882 | 0.78 | RORC (0.32) | P2RX7 | |
| SCHEMBL13691651 | 0.75 | CTSK (0.33) | — | |
| SCHEMBL9942884 | 0.73 | P2RX7 (0.34) | ELANEP2RX7CA1CA2LMNA | |
| SCHEMBL9900834 | 0.72 | LMNA (0.37) | ELANEP2RX7CA1CA2LMNA | |
| SCHEMBL9943048 | 0.70 | TP53 (0.35) | CA1CA2LMNAKDM4E | |
| SCHEMBL13691428 | 0.69 | RORC (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ELANE 2590/4885P2RX7 3911/4885CA1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.